论文部分内容阅读
目的 观察阿替普酶静脉溶栓联合依达拉奉注射液治疗急性脑梗死患者的临床效果.方法 将医院收治的急性脑梗死患者86例随机分为观察组和对照组, 每组43例.对照组给予阿替普酶溶栓治疗, 观察组给予阿替普酶静脉溶栓联合依达拉奉注射液治疗.比较2组治疗效果;治疗前、治疗后3 d抽取患者空腹静脉血液, 用酶联免疫吸附法测定其肿瘤坏死因子(TNF-α)、IL-8、IL-6、超敏C反应蛋白(hs-CRP)进行比较;记录不良反应发生情况.结果 观察组治疗总有效率为95. 35％, 高于对照组的69. 77％(P <0.01);治疗后, 2组TNF-α、IL-8、IL-6、hs-CRP水平较治疗前均降低, 且观察组上述炎性因子降低幅度大于对照组(P均 0.05).结论 阿替普酶静脉溶栓联合依达拉奉注射液治疗急性脑梗死患者效果显著, 可改善血清炎性因子, 安全性高, 疗效突出.“,”Objective To observe the clinical effect of Alteplase intravenous thrombolysis combined with edaravone in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into observation group and control group, 43 cases in each group. The control group was treated with Alteplase thrombolytic therapy, while the observation group was treated with Edaravone on the basis of the control group. The therapeutic effects of the two groups were compared. Fasting venous blood was collected before treatment and on the third day after treatment. TNFa, IL-8, IL-6 and hs-CRP were measured by ELISA and compared. Adverse reactions were recorded in both groups. Results The total effective rate of the observation group was 95. 35％, higher than 69. 77％ of the control group (P < 0. 01). After treatment, the levels of TNF-a, IL-8, IL-6 and hs-CRP in the two groups were lower than those in the control group, and the above indexes in the observation group were lower than those in the control group (P 0. 05). Conclusion Alteplase intravenous thrombolysis combined with Edaravone in the treatment of acute cerebral infarction patients has a significant effect, can improve the level of serum inflammatory factors, high safety, outstanding curative effect.